查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854612

生技藥品合約開發市場按服務類型、分子類型、治療領域、宿主系統、最終用戶和技術分類－2025-2032年全球預測

Biologics Contract Development Market by Service Type, Molecule Type, Therapeutic Area, Host System, End User, Technology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生技藥品合約開發市場將成長至 182.9 億美元，複合年成長率為 12.15%。

主要市場統計數據
基準年 2024 73億美元
預計年份：2025年 81.7億美元
預測年份：2032年 182.9億美元
複合年成長率 (%) 12.15%

為高階主管提供生技藥品合約開發領域的最新動態，闡明技術、監管和採購選擇的策略重點。

生技藥品合約開發領域正經歷重大變革，其驅動力包括科學創新、不斷變化的監管環境以及研發和生產能力獲取與部署方式的重新配置。本文將重點在於闡述塑造該產業的核心動態，並闡明經營團隊必須納入短期規劃和長期能力建構的策略考量。它強調了技術進步、供應鏈韌性以及內部研發與外包夥伴關係之間不斷變化的平衡之間的相互關係。

隨著包括日益複雜的單株抗體結構以及先進的細胞和基因療法在內的新型治療方法的出現，製程要求和設施設計正在改變。同時，製造商和研發人員面臨著產品品質、可比性和法規合規性方面日益嚴格的審查，這使得經驗豐富的合約研究合作夥伴的價值日益凸顯，他們能夠在縮短研發週期的同時規避技術風險。因此，企業領導者必須重新評估籌資策略，優先選擇能夠提供涵蓋製程開發、臨床生產和商業化規模生產的端到端解決方案的合作夥伴。

此做法承認宏觀經濟和政策因素與實際營運情況相互交織。貿易政策的變化、區域獎勵以及資本配置模式都會影響產能擴張的地點以及哪些技術會獲得優先投資。這些因素共同作用，既創造了差異化發展的機會，也帶來了加速能力發展的壓力。以下章節將更詳細地分析這些變化，以幫助經營團隊在尋求保持生技藥品研發和商業化勢頭時做出切合實際的選擇。

積極考慮影響生技藥品受託製造的技術、商業性和結構性變化。

生技藥品研發生態系統正經歷技術、商業性和結構上的變革，這些變革正在改變整個價值鏈的競爭格局。在技​​術方面，連續生產方法和一次性系統的應用正在重新定義製程架構和設施佈局，從而實現更大的產能彈性和更快的產品宣傳活動切換。這些技術變革，加上更複雜的上游和下游研發技術，需要整合製程知識和能力，以確保大規模生產中品質屬性的一致性。

在商業性，細胞和基因療法等複雜治療方法的興起，推動了對與客製化研發路徑緊密結合的臨床生產服務的需求。這使得能夠提供生產能力以及深厚的監管和分析專業知識的合作夥伴的戰略重要性日益凸顯。同時，支付方的監控和生命週期管理策略正促使申辦方從研發初期就重新評估其商業化計劃，並傾向於選擇與長期產品策略相契合的合約合作夥伴，而非交易型供應商。

從結構上看，特定領域的整合以及利基專業供應商的成長正在重塑供應商格局。能夠提供整合製程開發、多階段臨床生產支援以及快速擴大規模實現商業化生產的企業將擁有競爭優勢。同時，地緣政治的不確定性和供應鏈的脆弱性促使企業重新關注區域多元化和關鍵能力的近岸外包。總而言之，這些變革性的變化要求企業領導者重新評估夥伴關係，選擇性地投資策略技術，並建立適應性強的管治模式，以應對複雜性並加快產品進入臨床和市場的速度。

2025年美國關稅調整將如何改變生技藥品研發採購、供應鏈設計與位置決策的詳細分析

2025年實施的額外關稅和貿易政策調整，為參與生技藥品合約開發的機構帶來了新的營運和策略考量。關稅變化將影響專用設備、一次性組件和關鍵原料的進出口，可能增加採購計劃的複雜性，並要求更穩健的供應商多元化策略。因此，製造商和贊助商將重新審視其供應商組合和庫存政策，以保護其研發項目免受關稅波動的影響。

除了直接的成本影響外，關稅還會影響生產地點和資本配置的決策。鑑於成本結構和海關程序的變化，必須重新評估某些地區在設備和耗材採購方面的比較優勢。擁有靈活生產架構（例如模組化設備部署和可適應的製程平台）的公司更有能力適應這些變化。此外，關稅驅動的供應鏈變化凸顯了熟悉當地法規的成熟物流管道的重要性，這些管道可以縮短生技藥品製品跨境運輸的前置作業時間和降低相關營運風險。

監管和合約框架也需要更加密切關注。服務協議和供應商合約可能需要重新談判，以納入關稅轉嫁條款、前置作業時間調整、緊急條款等內容。因此，產業領導者正在加強跨職能團隊建設，包括採購、法律、監管和營運方面的專家，以確保對關稅的影響做出協調一致的應對。總之，雖然關稅不會改變生技藥品研發的基本科學挑戰，但它們確實會重塑採購、生產力計畫和長期策略投資的經濟效益和風險狀況。

透過全面的細分主導洞察，揭示服務類型、分子類別、治療領域、宿主系統、最終用戶和實行技術方面的能力差距和策略重點。

透過細緻的細分視角，我們可以揭示服務類型、分子類別、治療領域、宿主系統、最終用戶和賦能技術等方面的能力差距和策略機會所在。按服務類型分類，市場涵蓋臨床生產、商業化生產、填充和製程開發，其中臨床生產本身包括I期、II期和III期臨床試驗，而製程開發則分為下游開發和上游開發。這種細分凸顯了合作夥伴的重要性，該合作夥伴能夠無縫推進計劃，從早期工藝表徵到後期放大生產，再到最終的商業化生產，確保分析方法、可比性策略和品質系統的連續性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 採用一次性反應器技術可提高生物製藥生產的靈活性並降低污染風險
  • 利用模組化CDMO設施擴展細胞和基因治療生產服務，實現快速臨床規模化生產
  • 在生物製藥生產中應用連續層析法和灌註生物程序，以提高生產效率和成本效益。
  • 將人工智慧和機器學習整合到預測建模和流程開發中，以加速生物候選藥物的篩選
  • 針對mRNA疫苗和基因療法的專業填充和包裝服務日益成長，這些服務對低溫運輸要求非常嚴格。
  • 加強區域合約生產商與生物技術公司之間的合作，以應對複雜的全球生物製藥監管環境
  • 投資綠色生物製造舉措和永續實踐，以減少生物製藥生產對環境的影響
  • 實施數位雙胞胎技術和即時分析，實現端到端生物製藥供應鏈的可視性和風險管理
  • 專注於生物相似藥的CDMO（合約研發生產機構）的出現，為下一代治療性抗體提供先進的糖基化工程服務。
  • 整合基於區塊鏈的溯源解決方案，以確保生技藥品血清採購的透明度和合規性。

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章生技藥品合約開發市場（按服務類型分類）

  • 臨床生產
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業製造
  • 填充和精加工
  • 製程開發
    • 下游開發
    • 上游開發

第9章生技藥品合約開發市場（依分子類型分類）

  • 細胞和基因治療
  • 單株抗體
    • 雙重特異性
    • 共軛物
    • 裸
  • 重組蛋白
  • 疫苗
    • 細菌
    • mRNA
    • 病毒

第10章生技藥品合約開發市場（依治療領域分類）

  • 自體免疫疾病
  • 心血管系統
  • 感染疾病
    • 細菌
    • 病毒
  • 腫瘤學
    • 血液學
    • 固態腫瘤

第11章生技藥品合約開發市場（依宿主系統分類）

  • 哺乳動物
    • Cho 細胞
    • Ns0細胞
  • 微生物
    • 大腸桿菌
  • 酵母菌

第12章生技藥品合約開發市場（依最終用戶分類）

  • 生物製藥公司
  • 契約製造組織
  • 製藥公司

第13章生技藥品合約開發市場（依技術分類）

  • 連續製造
    • 灌注
    • 單一途徑
  • 免洗系統
  • 不銹鋼系統

第14章生技藥品合約開發市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章生技藥品合約開發市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國生技藥品合約開發市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Lonza Group Ltd
    • Catalent, Inc
    • Thermo Fisher Scientific Inc
    • Samsung Biologics Co., Ltd
    • Boehringer Ingelheim International GmbH
    • WuXi Biologics Ltd
    • Fujifilm Diosynth BIoTechnologies USA, Inc
    • AGC Biologics A/S
    • Recipharm AB
    • Rentschler Biopharma SE
Product Code: MRR-957C47F8FF75

The Biologics Contract Development Market is projected to grow by USD 18.29 billion at a CAGR of 12.15% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.30 billion
Estimated Year [2025] USD 8.17 billion
Forecast Year [2032] USD 18.29 billion
CAGR (%) 12.15%

An executive introduction to the evolving biologics contract development landscape that frames strategic priorities across technology, regulation, and sourcing choices

The biologics contract development landscape is undergoing a profound transformation driven by scientific innovation, evolving regulatory expectations, and a reconfiguration of how development and manufacturing capacity are sourced and deployed. This introduction synthesizes the core dynamics shaping the sector, framing the strategic considerations that executive teams must integrate into near-term planning and longer-term capability building. It clarifies the interplay between technological advances, supply chain resilience, and the shifting balance between in-house development and outsourced partnerships.

Emerging therapeutic modalities, including advanced cell and gene therapies alongside increasingly complex monoclonal antibody constructs, are altering process demands and facility designs. Concurrently, manufacturers and developers face heightened scrutiny around product quality, comparability, and regulatory compliance, which in turn elevates the value of experienced contract development partners who can navigate technical risk while compressing timelines. As a result, leaders must reassess sourcing strategies to prioritize partners capable of delivering end-to-end solutions spanning process development, clinical manufacturing, and commercial-scale production.

This introduction also recognizes the macroeconomic and policy factors that intersect with operational realities. Trade policy shifts, regional incentives, and capital allocation patterns will influence where capacity is expanded and what technologies receive preferential investment. Together, these forces create both opportunities for differentiation and pressure to accelerate capability development. The following sections unpack these shifts in greater detail to inform pragmatic choices for executives seeking to sustain momentum in biologics development and commercialization.

A forward-looking examination of the technical, commercial, and structural transformations reshaping contract development and manufacturing for biologics

The biologics development ecosystem is experiencing transformative shifts that are simultaneously technical, commercial, and structural, altering competitive positioning across the value chain. On the technical front, continuous manufacturing approaches and single-use system adoption are redefining process architectures and facility footprints, enabling greater flexibility in capacity utilization and faster changeovers between product campaigns. These technology shifts coincide with more sophisticated upstream and downstream development techniques that demand integrated process knowledge and capability to ensure consistent quality attributes at scale.

Commercially, the rise of complex modalities such as cell and gene therapies has expanded demand for bespoke development pathways and tightly coordinated clinical manufacturing services. This has elevated the strategic importance of partners that can provide not only manufacturing capacity but also deep regulatory and analytical expertise. In parallel, payer scrutiny and lifecycle management strategies are prompting sponsors to rethink commercialization plans early in development, which favors contract partners aligned to long-term product strategies rather than transactional suppliers.

Structurally, consolidation among certain segments and the growth of specialist niche providers are reshaping the supplier landscape. Firms that can offer integrated process development, clinical manufacturing support across multiple phases, and rapid scale-up to commercial manufacturing will hold a competitive edge. Meanwhile, geopolitical uncertainty and supply chain fragility are driving a renewed focus on regional diversification and nearshoring of critical capabilities. Taken together, these transformative shifts require leaders to re-evaluate partnerships, invest selectively in strategic technologies, and build adaptive governance models to manage complexity and accelerate time to clinic and market.

An in-depth analysis of how the 2025 United States tariff adjustments alter procurement, supply chain design, and location decisions for biologics development

The introduction of additional tariff measures and trade policy recalibrations in 2025 has introduced new operational and strategic considerations for organizations engaged in biologics contract development. Tariff changes affect inbound and outbound flows of specialized equipment, single-use components, and critical raw materials, which can increase the complexity of procurement planning and necessitate more robust supplier diversification strategies. Consequently, manufacturers and sponsors are reassessing vendor portfolios and inventory policies to insulate development programs from tariff-driven volatility.

Beyond direct cost implications, tariffs influence decisions about manufacturing location and capital deployment. Assumptions about the comparative advantage of particular regions for sourcing equipment or consumables must be revisited in light of altered cost structures and customs procedures. Firms with flexible manufacturing architectures, including capabilities for modular facility deployment and adaptable process platforms, are better positioned to respond to these shifts. Moreover, tariff-driven changes to supply chains amplify the importance of local regulatory familiarity and established logistics pathways, which can reduce lead times and the operational risks associated with cross-border movement of biologics materials.

Regulatory and contractual frameworks also require closer attention. Service agreements and supplier contracts may need renegotiation to account for tariff pass-through clauses, lead-time adjustments, and contingency provisions. Industry leaders are therefore strengthening cross-functional teams that include procurement, legal, regulatory, and operations professionals to ensure coherent responses to tariff impacts. In sum, while tariffs do not alter the fundamental scientific challenges of biologics development, they reshape the economics and risk profile of sourcing, capacity planning, and long-term strategic investments.

Comprehensive segmentation-driven insights that reveal capability gaps and strategic priorities across service types, molecule classes, therapeutic areas, host systems, end users, and enabling technologies

A nuanced segmentation lens reveals where capability gaps and strategic opportunities converge across service types, molecule classes, therapeutic areas, host systems, end users, and enabling technologies. Based on service type, the market encompasses clinical manufacturing, commercial manufacturing, fill-finish, and process development; clinical manufacturing itself spans Phase I, Phase II, and Phase III, while process development divides into downstream development and upstream development. This segmentation highlights the need for partners who can move projects seamlessly from early-phase process characterization through late-stage scale-up and commercial transfer, ensuring continuity of analytical methods, comparability strategies, and quality systems.

Based on molecule type, the landscape includes cell and gene therapies, monoclonal antibodies, recombinant proteins, and vaccines; within monoclonal antibodies, bispecific, conjugated, and naked formats present varying process and analytical challenges, and vaccines differentiate across bacterial, mRNA, and viral platforms. These distinctions drive divergent technical requirements-cell and gene therapies require specialized viral vector production and cold chain logistics, bispecific antibodies often demand advanced purification and potency assays, and mRNA vaccines hinge on lipid nanoparticle formulation and stringent RNA integrity controls-thereby influencing supplier capability priorities and facility design.

Based on therapeutic area, the market covers autoimmune disorders, cardiovascular, infectious diseases, and oncology; infectious diseases further split into bacterial and viral categories, while oncology divides into hematology and solid tumors. Therapeutic focus affects clinical manufacturing cadence, batch sizes, and development timelines; oncology programs, particularly in hematology, may require rapid iterative production for personalized therapies, whereas infectious disease vaccine campaigns often prioritize surge capacity and platform scalability.

Based on host system, host options include mammalian, microbial, and yeast; mammalian systems further specify CHO cells and NS0 cells, and microbial systems highlight E. coli. Host selection informs upstream process configuration, contamination control regimes, and downstream purification strategies, with mammalian hosts typically used for complex glycosylated proteins and microbial hosts offering cost-effective expression for certain recombinant products.

Based on end user, the market serves biopharmaceutical companies, contract manufacturing organizations, and pharmaceutical companies; understanding end-user needs clarifies service packaging, from flexible clinical supply arrangements for small biotech sponsors to integrated, regulatory-ready commercial supply chains for larger developers. Finally, based on technology, capabilities range across continuous manufacturing, single-use systems, and stainless steel systems, with continuous manufacturing itself encompassing perfusion and single-pass modalities. Technology selection affects facility footprint, capital intensity, and operational throughput, and it often determines the speed at which a partner can support transitions between clinical and commercial phases. Collectively, these segmentation dimensions underscore the imperative for strategic alignment between sponsor programs and partner capabilities to minimize technical risk and optimize development timelines.

Strategic regional intelligence that maps capacity strengths, regulatory nuances, and supply chain advantages across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to shape where biologics development activities concentrate and how organizations structure their global operations. In the Americas, innovation hubs and a dense ecosystem of clinical trials create sustained demand for clinical manufacturing and rapid analytics, while regulatory frameworks emphasize data integrity and process validation practices that support accelerated development pathways. This region also benefits from proximity to major sponsors and venture capital, which reinforces a pipeline of early-stage programs requiring specialized contract development support.

Europe, the Middle East & Africa features diverse regulatory environments and a mix of established biomanufacturing clusters alongside emerging capabilities. In several European markets, incentives for bioproduction and investments in advanced manufacturing infrastructure support the adoption of continuous processing and single-use technologies. Regional collaboration initiatives and harmonization efforts can reduce barriers for cross-border supply, but organizations must still navigate differing national requirements and logistics complexities when planning multi-site development and commercial supply strategies.

Asia-Pacific continues to expand its role as both a manufacturing base and an innovation center, with notable growth in contract manufacturing capacity, investments in single-use systems, and an increasing number of facilities certified to international regulatory standards. The region's supply chain strengths, including components and consumables manufacturing, offer advantages for sponsors seeking diversified sourcing and competitive cost structures. However, regulatory pathways and market access conditions vary substantially across jurisdictions, prompting sponsors and contract developers to build localized regulatory expertise and regional partnerships to ensure timely program progression and compliance.

Across regions, strategic choices will hinge on balancing access to talent, regulatory alignment, supply chain resilience, and proximity to clinical trial networks. Firms that develop regional playbooks tailored to these considerations will be better positioned to support sponsors across development stages and to respond to shifting policy and economic environments.

Critical competitive insights into how technology investment, regulatory depth, and geographic footprint create differentiation among contract development and manufacturing organizations

Competitive dynamics among contract development and manufacturing organizations are defined by differentiation in technology platforms, depth of regulatory experience, and the breadth of integrated services offered. Leading providers prioritize investments in advanced analytics, scalable single-use systems, and process intensification techniques to reduce cycle times and improve product quality consistency. These investments are often complemented by strategic partnerships and capability co-development arrangements that accelerate access to novel modalities and analytical methods.

Another axis of differentiation lies in quality systems and regulatory track records. Organizations with established compliance histories across major regulatory jurisdictions can facilitate smoother program transitions from clinical phases to commercial supply, which is particularly valuable for sponsors seeking global launches. In addition, providers that offer value-added services-such as comparability study design, stability testing strategies, and regulatory submission support-are increasingly preferred over purely transactional suppliers because they reduce coordination overhead and technical risk for sponsors.

Operational resilience and geographic footprint also play a critical role. Firms with multi-site capabilities can offer redundancy and surge capacity, which is crucial for vaccine programs or personalized therapies requiring rapid turnarounds. At the same time, niche specialists focused on particular modalities or host systems carve out defensible positions by developing deep technical expertise and proprietary process knowledge. Collectively, these strategic approaches define the competitive map and inform how sponsors select partners based on alignment to program complexity, timeline urgency, and long-term commercialization plans.

Actionable strategic recommendations for industry leaders to align technology investments, operational resilience, and partnership models for scalable biologics development

Industry leaders must adopt actionable strategies that reconcile innovation velocity with operational robustness to capture value in biologics development. First, prioritize technology roadmaps that balance continuous processing and single-use flexibility with selective investments in stainless steel systems where long-term high-volume production justifies the capital outlay. Align these technology choices with product portfolios and anticipated lifecycle requirements to avoid stranded assets and ensure scalable capacity.

Second, build cross-functional governance mechanisms that bring procurement, quality, regulatory, and operations together early in program planning. This integrated approach reduces handoff risks, shortens decision cycles, and creates clearer escalation paths for technical issues. Third, enhance supplier diversity by qualifying alternate vendors for critical consumables and equipment, and by establishing regional sourcing strategies that mitigate tariff and logistics exposures. Combined with scenario-based inventory strategies, these actions strengthen supply chain resilience.

Fourth, invest in talent and process knowledge transfer programs that accelerate sponsor-partner integration, particularly for complex modalities such as cell and gene therapies and novel antibody constructs. This includes structured training, collaborative development sprints, and shared analytics platforms that preserve institutional knowledge and enable rapid troubleshooting. Finally, adopt partnership models that align incentives around long-term product success, including risk-sharing arrangements for scale-up and commercialization phases. These practical steps will enable organizations to reduce technical risk, accelerate timelines, and capture strategic value from emerging biologics opportunities.

A transparent, multi-source research methodology combining expert interviews, technical literature synthesis, and operational assessment to ensure actionable analysis

The research approach underpinning this analysis combines qualitative expert interviews, technical literature synthesis, and cross-functional operational assessment to ensure a robust and actionable perspective. Primary inputs included discussions with process development scientists, manufacturing leaders, regulatory affairs professionals, and supply chain experts, which provided firsthand insight into current pain points, technology adoption patterns, and regional operational differences. These conversations were structured to surface both tactical challenges and strategic imperatives across clinical and commercial stages.

Secondary research focused on technical publications, regulatory guidance documents, and publicly available case studies that illustrate best practices in process intensification, facility design, and quality systems. Emphasis was placed on triangulating findings across sources to validate trends and to identify areas of divergence between reported capabilities and operational realities. Analytical frameworks were applied to assess technology maturity, supply chain exposure, and the alignment of end-user needs with provider offerings.

Throughout the research process, care was taken to ensure transparency of assumptions and to document methodological limitations. Where gaps existed in public information, targeted expert validation helped refine interpretations and reduce uncertainty. The result is a synthesis that balances technical rigor with practical relevance, providing executives with clear diagnostic insight and a tested set of strategic considerations to guide decision-making in biologics contract development.

A conclusive synthesis highlighting imperative focus areas for leaders to secure resilient, scalable, and commercially viable biologics development pathways

In conclusion, the biologics contract development environment is at an inflection point where technological innovation, regulatory complexity, and geopolitical shifts converge to reshape strategic decision-making. Sponsors and providers who align technology investments with product modality demands, who strengthen cross-functional governance, and who diversify supply chains will navigate this period with greater agility and lower operational risk. The ability to integrate process development, clinical manufacturing, and commercial readiness into cohesive program plans will determine which organizations accelerate timelines and capture value.

Looking ahead, success will favor those who adopt adaptive facility designs, invest in advanced analytics, and cultivate partnerships that share both expertise and risk. Regional strategies should be calibrated to regulatory realities and supply chain advantages, and contingency planning should account for policy-driven disruptions such as tariff adjustments. By focusing on these core imperatives, industry leaders can translate emerging trends into durable competitive advantage and ensure resilient pathways from discovery through commercial supply.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of single-use bioreactor technology to enhance flexibility and reduce contamination risks in biologics manufacturing
  • 5.2. Expansion of cell and gene therapy manufacturing services through modular CDMO facilities for rapid clinical scale-up
  • 5.3. Implementation of continuous chromatography and perfusion bioprocessing for increased productivity and cost efficiencies in biologics production
  • 5.4. Integration of AI and machine learning in process development for predictive modeling and accelerated biologic candidate selection
  • 5.5. Growth of specialized fill-finish services tailored for mRNA vaccines and gene therapies with stringent cold chain requirements
  • 5.6. Rising collaborations between regional CMOs and biotech firms to navigate complex global biologics regulatory pathways
  • 5.7. Investment in green biomanufacturing initiatives and sustainable practices to reduce environmental impact of biologics production
  • 5.8. Deployment of digital twin technology and real-time analytics for end-to-end biologics supply chain visibility and risk management
  • 5.9. Emergence of biosimilar-focused CDMOs offering advanced glycoengineering services for next-generation therapeutic antibodies
  • 5.10. Integration of blockchain-enabled traceability solutions to ensure transparency and compliance in biologics serum sourcing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Contract Development Market, by Service Type

  • 8.1. Clinical Manufacturing
    • 8.1.1. Phase I
    • 8.1.2. Phase II
    • 8.1.3. Phase III
  • 8.2. Commercial Manufacturing
  • 8.3. Fill Finish
  • 8.4. Process Development
    • 8.4.1. Downstream Development
    • 8.4.2. Upstream Development

9. Biologics Contract Development Market, by Molecule Type

  • 9.1. Cell Gene Therapy
  • 9.2. Monoclonal Antibodies
    • 9.2.1. Bispecific
    • 9.2.2. Conjugated
    • 9.2.3. Naked
  • 9.3. Recombinant Proteins
  • 9.4. Vaccines
    • 9.4.1. Bacterial
    • 9.4.2. Mrna
    • 9.4.3. Viral

10. Biologics Contract Development Market, by Therapeutic Area

  • 10.1. Autoimmune Disorders
  • 10.2. Cardiovascular
  • 10.3. Infectious Diseases
    • 10.3.1. Bacterial
    • 10.3.2. Viral
  • 10.4. Oncology
    • 10.4.1. Hematology
    • 10.4.2. Solid Tumors

11. Biologics Contract Development Market, by Host System

  • 11.1. Mammalian
    • 11.1.1. Cho Cells
    • 11.1.2. Ns0 Cells
  • 11.2. Microbial
    • 11.2.1. E Coli
  • 11.3. Yeast

12. Biologics Contract Development Market, by End User

  • 12.1. Biopharmaceutical Companies
  • 12.2. Contract Manufacturing Organizations
  • 12.3. Pharmaceutical Companies

13. Biologics Contract Development Market, by Technology

  • 13.1. Continuous Manufacturing
    • 13.1.1. Perfusion
    • 13.1.2. Single Pass
  • 13.2. Single Use Systems
  • 13.3. Stainless Steel Systems

14. Biologics Contract Development Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Biologics Contract Development Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Biologics Contract Development Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Lonza Group Ltd
    • 17.3.2. Catalent, Inc
    • 17.3.3. Thermo Fisher Scientific Inc
    • 17.3.4. Samsung Biologics Co., Ltd
    • 17.3.5. Boehringer Ingelheim International GmbH
    • 17.3.6. WuXi Biologics Ltd
    • 17.3.7. Fujifilm Diosynth Biotechnologies U.S.A., Inc
    • 17.3.8. AGC Biologics A/S
    • 17.3.9. Recipharm AB
    • 17.3.10. Rentschler Biopharma SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BIOLOGICS CONTRACT DEVELOPMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. BIOLOGICS CONTRACT DEVELOPMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOLOGICS CONTRACT DEVELOPMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY E COLI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY E COLI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY E COLI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY E COLI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY E COLI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY E COLI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 201